Anika Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Anika Therapeutics

09/05/2023 23:31

* Anika Therapeutics Inc  ANIK.OQ  reported a quarterly
adjusted
loss of 47 cents​​ per share for the quarter ended in March. The
mean expectation of three analysts for the quarter was for a
loss of 30 cents per share.
    * Revenue rose 3.4% to $37.92 million from a year ago;
analysts
expected $37.28 million. 
    * Anika Therapeutics Inc's reported EPS for the quarter was
a loss
of 71 cents​.
    * The mean earnings estimate of analysts had fallen by
about 25%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Anika Therapeutics Inc shares had fallen by 9.5% this
quarter and lost 12.2% so far this year.
    * The company reported a quarterly loss of $10.35 million.
    * Wall Street's median 12-month price target for Anika
Therapeutics Inc is $33.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
9 at 10:30 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.30          -0.47          Missed
 Dec. 31 2022      -0.24          -0.34          Missed
 Sep. 30 2022      -0.25          -0.15          Beat
 Jun. 30 2022      -0.23          -0.20          Beat